Type2 Diabetes Mellitus Clinical Trial
Official title:
Effect of Henagliflozein on Hepatic Fat Content in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized, Controlled Clinical Trial
This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD). Sponsored by Zhujiang Hospital of Southern Medical University, this study is a multi-center, randomized, controlled clinical trial, aiming at exploring the difference in the reduction of liver fat content in the subjects compared with the control group after 24 weeks of treatment. Subjects from different medical centers diagnosed with T2DM and NAFLD will be randomly assigned to the treatment or control group in a 1:1 ratio, and subsequently initiate the intervention period of 24 weeks. In this trial, patients will be treated with 10 mg of Henagliflozein + metformin and 5 mg of Linagliptin + metformin as control, and the dose of metformin will be customized at 500-1500mg according to their individual blood glucose level. The check-points are set at the 8th, 16th and 24th week of the follow-up after the treatment, and nutritionists are available to provide dietary and exercise guidance.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04082091 -
Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
|
||
| Active, not recruiting |
NCT02248311 -
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
|
N/A | |
| Completed |
NCT02653300 -
A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)
|
Phase 2 | |
| Completed |
NCT03655535 -
Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes
|
Phase 2 | |
| Completed |
NCT03256747 -
Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes
|
N/A | |
| Withdrawn |
NCT03675074 -
Neujia Anastomosis for Treatment of Obesity and Type II Diabetes
|
N/A | |
| Completed |
NCT05343767 -
Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus
|
N/A | |
| Withdrawn |
NCT03190798 -
Effects of Canagliflozin on Intravascular Volume and Hemodynamics
|
Phase 4 | |
| Withdrawn |
NCT03437330 -
Empagliflozin Effect on Glucose Toxicity
|
Phase 4 | |
| Withdrawn |
NCT03008395 -
Empowerment, Motivation and Medical Adherence (EMMA).
|
N/A | |
| Not yet recruiting |
NCT05539066 -
AI Health Assistant and Type 2 Diabetes
|
N/A | |
| Completed |
NCT03682445 -
Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus
|
N/A | |
| Not yet recruiting |
NCT03239119 -
The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT03259789 -
Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
|
Phase 3 | |
| Recruiting |
NCT03506230 -
Financial Incentives for Low Socioeconomic Diabetic Patients
|
N/A | |
| Completed |
NCT03072407 -
MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM
|
Phase 1 | |
| Completed |
NCT05668442 -
Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
|
||
| Completed |
NCT02964572 -
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
|
N/A | |
| Completed |
NCT02956044 -
Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin
|
Phase 1 | |
| Completed |
NCT02628392 -
A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
|
N/A |